BOSTON and LONDON, May 15, 2025 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (Nasdaq: AKTX), a biotechnology company ...

Company’s PlaCCine® technology platform demonstrates better durability and other advantages compared to mRNA vaccines Results further validate PlaCCine as a novel vaccine platform with potential ...

Stacy Lindborg; President, Chief Executive Officer and Board Director; Imunon Inc. Presentation. Operator. Good morning. My name is Dave, and I will be your operator ...

Imunon, Inc. ( NASDAQ: IMNN) Q1 2025 Earnings Conference Call May 12, 2025 11:00 AM ET Peter Vozzo - ICR Healthcare, Investor Relations Stacy Lindborg - President & Chief Executive Officer Douglas ...

Q1 2025 Management View President & CEO Stacy Lindborg announced the initiation of the first clinical site in Imunon's ...

First site initiated for Phase 3 OVATION 3 study of IMNN-001 in treatment of newly diagnosed advanced ovarian cancer New data from Phase 2 OVATION 2 study of IMNN-001 accepted for oral presentation at ...

LiveOne Inc (LVO) is expected to report $-0.04 for 4Q. Lyell Immunopharma Inc (LYEL) is expected to report $-0.20 for 1Q. Macerich Co (MAC) is expected to report $-0.09 for 1Q. Mineralys Therapeutics ...

Analysts estimate that Imunon will report an earnings per share (EPS) of $-0.36. Investors in Imunon are eagerly awaiting the ...

The first trial site has been initiated in the pivotal phase 3 OVATION 3 study which will investigate IMNN-001 for newly ...

Company currently initiating additional trial sites and working with study investigators to enroll participants IMNN-001 is the first and only immunotherapy to show meaningful overall survival benefit ...

The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...

LAWRENCEVILLE, N.J., April 21, 2025 (GLOBE NEWSWIRE) -- IMUNON, Inc. (IMNN), a clinical-stage company in Phase 3 development of its DNA-mediated immunotherapy, today announced that an abstract ...